Archive · 20 Aug 2025
Polymed Focuses on India, Targets 40% Revenue Share by 2030
Polymed, an Indian medical device company, is growing.
They want India to bring in more of their money, about 40% by 2030, while still selling a lot in other places like the US.
To do this, they are spending money to make their factories bigger and smarter, and buying other companies.
They want to make products in India that are as good as those made elsewhere so that India doesn't have to buy as many from other countries.
They are also doing well financially, with more sales and profit than last year.
They are aiming for a strong presence in India, more business in the US, and focus on creating new and improved products.
Polymed plans to increase India's revenue contribution to 40% by 2030.
The company is investing ₹500 crore in capacity expansion and ₹250 crore in acquisitions.
Polymed aims to reduce India's reliance on medical device imports.
The US remains a key market, alongside expansion in Europe, Asia, and Africa.
In FY25, Polymed's consolidated revenue was ₹17,59 crore, with significant growth in exports, domestic market, EBITDA, and profit after tax.
- Who
- Polymed, an Indian medtech company.
- What
- Polymed is expanding its global presence and aiming to increase revenue from India.
- When
- By 2030, for FY25 the company's revenue was ₹17,59 crore.
- Where
- The company is expanding in India, the US, Europe, Asia, and Africa.
- Why
- To capitalize on the growing healthcare demand, reduce reliance on imports, and strengthen its market position.
- Revenue in FY25
- ₹17,59 crore
- India revenue target
- 40% by 2030
- Capex plan
- ₹500 crore
- Acquisition fund
- ₹250 crore
- FY25 Export Growth
- 24%
- FY25 Domestic Market Growth
- 18.6%
- FY25 EBITDA margin
- 27.1%
- Liquidity as of June 2025
- ₹1,248 crore